The immunosuppressants segment by drug class is estimated to lead the market growth during the forecast period.
According to this study, the Middle East and Africa multiple sclerosis therapeutics market is expected to reach US$ 2,027.86 million by 2027 from US$ 1,319.08 million in 2019; it is estimated to grow at a CAGR of 5.7% from 2020 to 2027. The report highlights trends prevailing in the Middle East and Africa multiple sclerosis therapeutics market and the factors driving market along with those that act as hindrances.
The Middle East and Africa multiple sclerosis therapeutics market, by drug class, is segmented into immunosuppressant and immunomodulators. The immunomodulators segment held the largest share of the market in 2019, whereas the immunosuppressants segment is anticipated to register the highest CAGR in the market during the forecast period.
Multiple sclerosis (MS) is a chronic disease that affects the brain, spinal cord, and optic nerves. Studies show that there is an increase in the prevalence of multiple sclerosis across the Middle East and African countries. In recent years, various measures and efforts have been taken to create awareness and educate people regarding neurological diseases, which are facilitating patients to access suitable medications and treatments for such conditions. The Multiple Sclerosis Foundation and affiliated groups have initiated National MS Education and Awareness Month, which is observed in March since 2003 to increase awareness about the disease. The goal of this program is to promote an understanding of Multiple Sclerosis and help the patients in making educated decisions of its treatment. Also, the National MS Society created and launched the “MS Kills Connection > The report segments in Middle East and Africa Multiple Sclerosis Therapeutics Market as follows:
By Drug Class
By Route of Administration
By Distribution Channel
By Country
According to this study, the Middle East and Africa multiple sclerosis therapeutics market is expected to reach US$ 2,027.86 million by 2027 from US$ 1,319.08 million in 2019; it is estimated to grow at a CAGR of 5.7% from 2020 to 2027. The report highlights trends prevailing in the Middle East and Africa multiple sclerosis therapeutics market and the factors driving market along with those that act as hindrances.
The Middle East and Africa multiple sclerosis therapeutics market, by drug class, is segmented into immunosuppressant and immunomodulators. The immunomodulators segment held the largest share of the market in 2019, whereas the immunosuppressants segment is anticipated to register the highest CAGR in the market during the forecast period.
Multiple sclerosis (MS) is a chronic disease that affects the brain, spinal cord, and optic nerves. Studies show that there is an increase in the prevalence of multiple sclerosis across the Middle East and African countries. In recent years, various measures and efforts have been taken to create awareness and educate people regarding neurological diseases, which are facilitating patients to access suitable medications and treatments for such conditions. The Multiple Sclerosis Foundation and affiliated groups have initiated National MS Education and Awareness Month, which is observed in March since 2003 to increase awareness about the disease. The goal of this program is to promote an understanding of Multiple Sclerosis and help the patients in making educated decisions of its treatment. Also, the National MS Society created and launched the “MS Kills Connection > The report segments in Middle East and Africa Multiple Sclerosis Therapeutics Market as follows:
By Drug Class
- Immunosuppressant
- Immunomodulators
By Route of Administration
- Injectable
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
By Country
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Table of Contents
1. Introduction
3. Research Methodology
4. Middle East and Africa Multiple Sclerosis Therapeutics- Market Landscape
5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics
6. Multiple Sclerosis Therapeutics Market - Middle East and Africa Analysis
7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class
8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration
9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel
10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 - Middle East and Africa Analysis
11. Impact of COVID-19 Pandemic on Middle East and Africa Multiple Sclerosis Therapeutics Market
12. Industry Landscape
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- F. HOFFMANN-LA ROCHE LTD
- Biogen
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 128 |
Published | May 2021 |
Forecast Period | 2019 - 2027 |
Estimated Market Value ( USD | $ 1319.08 Million |
Forecasted Market Value ( USD | $ 2027.86 Million |
Compound Annual Growth Rate | 5.7% |
Regions Covered | Africa, Middle East |